News
ERS Genomics and IRBM sign CRISPR/Cas9 license agreement
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio. IRBM is a drug discovery CRO with expertise ranging from target validation and hit finding to preclinical candidate nomination across […]